About XMedius
XMedius was founded in 1993 and is based in Montreal, Canada. Operations are centered in the pharmaceutical sector, where medications for renal disease and dialysis products are produced. A portfolio including alpha-ketoanalogue tablets and sevelamer carbonate tablets is maintained. Products undergo rigorous quality checks to comply with industry standards. The focus remains on renal disease treatment within the healthcare domain.
- Headquarter Montreal, Canada
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Open Text Corporation
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of XMedius
Detailed funding history for XMedius
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in XMedius
XMedius has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include OpenText and StoneCalibre.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Cloud-based enterprise information management and GRC solutions are provided.
|
Locked | Locked | Locked | |
|
StoneCalibre is recognized as an international private investment firm.
|
Locked | Locked | Locked |
Investor details for XMedius
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by XMedius
Investment portfolio details for XMedius
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - XMedius
Detailed financials for XMedius
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xmedius Comparisons
Peer comparison for XMedius
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of XMedius
Detailed competitors of XMedius
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xmedius
Complete news archive for XMedius
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XMedius
XMedius was founded in 1993.
XMedius is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
XMedius was founded in 1993 and is based in Montreal, Canada. Operations are centered in the pharmaceutical sector, where medications for renal disease and dialysis products are produced. A portfolio including alpha-ketoanalogue tablets and sevelamer carbonate tablets is maintained. Products undergo rigorous quality checks to comply with industry standards. The focus remains on renal disease treatment within the healthcare domain.
XMedius has 2 investors. Key investors include OpenText, and StoneCalibre.